Advertisement

Diabetology International

, Volume 7, Issue 1, pp 1–3 | Cite as

Diabetic nephropathy and transcription factors

  • Yuichi MakinoEmail author
  • Masakazu Haneda
Editorial
  • 759 Downloads

Diabetic nephropathy (DN) is a major microvascular complication of diabetes mellitus (DM) and is an important cause of increased morbidity and mortality in patients with DM. Multiple factors, including an interaction between hyperglycemia-induced metabolic and hemodynamic changes [1] and genetic predisposition [2], have been shown to contribute to the development of DN. Currently, the mainstay of therapy for DN is improving glucose control and lowering systemic blood pressure with renin–angiotensin system inhibitors. However, despite those therapeutic regimens, the prevalence of DN has been increasing, and novel strategies are urgently needed.

DN is primarily glomerular injury, which is histologically defined as glomerular basement membrane thickening and excess accumulation of mesangial extracellular matrix proteins, although tubular injury or tubulointerstitial fibrosis is also a prominent component of the disease [3, 4]. Hyperglycemia present in the diabetic milieu induces a number of pathways, such as the activation of protein kinase C [5], accumulation of inflammatory mediators or growth factors [6] and advanced glycation end products (AGEs) [7], and the generation of reactive oxygen species (ROS) [8], in a variety of cell types in the kidney. Nevertheless, knowledge of the mechanism of gene regulation that elicits the biological response to glucose-mediated biochemical derangements is lacking. Recently, investigations in mesangial cells and in glomerular cells in vitro and in vivo have highlighted transcription factors that participate in the regulation of gene expression in diabetic circumstances.

For example, the Smad family of proteins, including Smad1 and Smad3, are activated in response to stimuli such as transforming growth factor beta (TGF-β) and AGEs to upregulate the production of extracellular matrix proteins by mesangial cells at the transcriptional level [9, 10, 11]. The transcription factor NF-κB is activated by cellular stimulation with ROS or cytokines induced by high glucose, and contributes to microinflammation of glomeruli [12]. STAT1 and STAT3, which are activated by high glucose or by increased angiotensin II in glomerular mesangial cells, are implicated in the production of extracellular matrix proteins and control of cellular growth [13].

Diverse cellular signaling pathways may converge on a transcription factor, and transcriptional dysregulation in the diabetic kidney can occur at multiple levels, including alterations in upstream signals or the transcription factor itself. In this respect, transcription factors are the final effector proteins at the site of gene regulation to mediate the cellular responses to pathogenic factors in diabetes. Therefore, transcription factors may represent attractive therapeutic targets that could circumvent many of the problems with signal redundancy and crosstalk that are often experienced in therapies targeting upstream of the cellular signals.

Despite the apparent progress in this field of research, difficulties in developing strategies for “drugging” transcription factors have been encountered. Some transcription factors, such as estrogen receptor in endocrine therapy for cancers [14] and glucocorticoid receptor in anti-inflammation or immunosuppression therapy [15], are directly regulated by, e.g., synthetic steroid ligands. For the other transcription factors, however, indirect targeting designs are available: decoy oligonucleotides to disrupt STAT3– or NF-κB–DNA interactions [16, 17], quadruplex stabilizer in c-Myc regulation [18], and small interfering RNA or antisense oligonucleotide technology for many other factors [19]. Since the issue of the delivery of the drug or the molecule is important in a small nucleic acid based strategy, more realistic options for targeting transcription factors are required.

Recently, it was reported that high glucose induces O-GlcNAcylation of carbohydrate response element binding proteins (ChREBP) in rat mesangial cells [20]. ChREBP is a basic helix–loop–helix/leucine zipper transcription factor that is expressed in several metabolically relevant tissues, including liver, adipocytes, pancreatic β-cells, and certain cancer cells, and is a mediator of glucose-responsive gene activation [21, 22, 23]. Upon activation by glucose, ChREBP translocates from the cytosol into the nucleus, thereby forming a heterodimer with Max-like protein X (Mlx) that binds to the carbohydrate response element (ChRE) for transcriptional regulation of genes associated with glucose, lipid, fatty acid, and steroid metabolism [24]. We previously reported that, in response to high glucose, ChREBP upregulates hypoxia-inducible transcription factor (HIF)-1α mRNA expression via direct binding to the HIF-1α gene promoter in diabetic mesangial cells [25]. Upregulated HIF-1α in turn induces its target genes, such as connective tissue growth factor and plasminogen activator inhibitor-1, promoting extracellular matrix accumulation in diabetic glomeruli. The discovery of the ChREBP–HIF-1α axis demonstrated a previously unknown role of HIF-1α in diabetic glomerulopathy and provided a mechanism for the diversity of glucose signal outputs that leads to diabetic kidney injury [25]. In addition, we found that ChREBP transcriptionally upregulates platelet-derived growth factor C for the production of type IV and VI collagens in mesangial cells (unpublished observation). O-GlcNAcylation of ChREBP in mesangial cells, induced either by high glucose or the drug O-(2-acetamido-2-deoxy-d-glucopyranosylidene)amino N-phenylcarbamate (PUGNAc), augments protein stability, transcriptional activity, and nuclear translocation of ChREBP, resulting in the upregulation of ChREBP targets including HIF-1α and genes downstream [20]. Importantly, 6-diazo-5-oxonorleucine (DON), a drug that decreases O-GlcNAcylation, mitigated HIF-1α induction and fibrotic response via O-GlcNAcylated ChREBP in mesangial cells in high ambient glucose [20]. Although there are concerns over cell-specific drug delivery, it is worth noting that pharmacological modification of ChREBP has emerged in anticipation of it becoming a therapeutic strategy for DN.

Another example of the evolving therapeutic tactics employed for DN is the augmentation of antioxidant defenses by upregulation of the Nrf2/Keap1 pathway [26]. Nrf2 is a transcription factor that controls the expression of cytoprotective genes harboring the antioxidant response element (ARE) in their promoters. Nrf2 is latently sequestered in the cytoplasm by the inhibitory protein Keap1. Upon cellular exposure to oxidative or electrophilic stress, Nrf2 dissociates from Keap1 and migrates into the nucleus, where it heterodimerizes with other transcription factors such as small Maf proteins and then binds to ARE in the gene promoter. Nrf2 activates the transcription of genes encoding antioxidant enzymes and phase II detoxifying enzymes, thereby eliciting protection against cellular threats such as oxidative stress and inflammation that are common in diabetic milieu [26]. Indeed, Nrf2-knockout mice were observed to suffer severe streptozotocin-induced diabetic kidney complications [27]. Moreover, pharmacological or dietary activation of Nrf2 resulted in the amelioration of kidney damage in a diabetic mouse model through the reduction of oxidative damage or ROS in those animals [28]. A good illustration of the impact of an Nrf2 activator in the treatment of DN was provided by a recent phase 2 clinical trial in which bardoxolone methyl, a potent synthetic triterpenoid that activates Nrf2, was administered to patients with type 2 diabetes and chronic kidney disease [29]. Estimated GFR, blood pressure, and urinary albumin-to-creatinine ratio increased significantly while body weight decreased significantly in the bardoxolone methyl group as compared with the placebo group, indicating a promising positive effect of Nrf2-targeted therapy for DN [29]. Unexpectedly, however, a phase 3 clinical trial of bardoxolone methyl was terminated prematurely due to unexplained adverse cardiovascular events. That said, the potentially valuable properties of bardoxolone methyl in the treatment of diabetes and chronic kidney disease has motivated the organization of a new domestic phase 2 clinical trial of this Nrf2 activator in Japan.

In conclusion, progress is being made in research aiming at the modulation of transcription factors with potential clinical benefits, although the issue of druggability must still be resolved. Precisely targeting transcription factors may minimize the redundancy of mechanisms downstream of complex signaling pathways, thus potentially improving therapeutic approaches. The development of new concepts and technology for targeting transcription factors is needed to create novel therapies for DN.

Notes

Compliance with ethical standards

Conflict of interest statement

M. Haneda received lecture fees from Boehringer Ingelheim GmbH, Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Taisho Pharmaceutical Co., Ltd., Sanofi K.K., Astellas Pharma Inc., Kowa Pharmaceutical Co., Ltd., Novartis Pharma K.K., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., and Taisho Toyama Pharmaceutical Co., Ltd.

M. Haneda received research grants from Boehringer Ingelheim GmbH, Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Taisho Pharmaceutical Co., Ltd., Sanofi K.K., Astellas Pharma Inc., Kowa Pharmaceutical Co., Ltd., Novartis Pharma K.K., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Eli Lilly and Co., Kissei Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Shionogi & Co. Ltd., and Daiichi Sankyo Co. Ltd.

Y. Makino declares that he has no conflict of interest.

Ethics policy

This article does not report any studies with human or animal subjects that were performed by any of the authors.

References

  1. 1.
    Gnudi L, Viberti G, Raij L, et al. GLUT-1 overexpression: link between hemodynamic and metabolic factors in glomerular injury? Hypertension. 2003;42:19–24.CrossRefPubMedGoogle Scholar
  2. 2.
    Mueller PW, Rogus JJ, Cleary PA, et al. Genetics of kidneys in diabetes (GoKinD) study: a genetics collection available for identifying genetic susceptibility factors for diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol. 2006;17:1782–90.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol. 2003;14:1358–73.CrossRefPubMedGoogle Scholar
  4. 4.
    Maezawa Y, Takemoto M, Yokote K. Cell biology of diabetic nephropathy: roles of endothelial cells, tubulointerstitial cells and podocytes. J Diabetes Investig. 2015;6:3–15.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Haneda M, Koya D, Kikkawa R. Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway. Am J Kidney Dis. 2001;38(4 Suppl 1):S178–81.CrossRefPubMedGoogle Scholar
  6. 6.
    Murphy M, Godson C, Cannon S, et al. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem. 1999;274:5830–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Forbes JM, Cooper ME, Oldfield MD, et al. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol. 2003;14:S254–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Kiritoshi S, Nishikawa T, Sonoda K, et al. Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy. Diabetes. 2003;52:2570–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Mima A, Arai H, Matsubara T, et al. Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy. Diabetes. 2008;57:1712–22.CrossRefPubMedGoogle Scholar
  10. 10.
    Hong SW, Isono M, Chen S, et al. Increased glomerular and tubular expression of transforming growth factor-β1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol. 2001;158:1653–63.CrossRefPubMedGoogle Scholar
  11. 11.
    Matsubara T, Araki M, Abe H, et al. Bone morphogenetic protein 4 and Smad1 mediate extracellular matrix production in the development of diabetic nephropathy. Diabetes. 2015;64:2978–90.CrossRefPubMedGoogle Scholar
  12. 12.
    Yang B, Hodgkinson A, Oates PJ, et al. High glucose induction of DNA-binding activity of the transcription factor NFκB in patients with diabetic nephropathy. Biochem Biophys Acta. 2008;1782:295–302.PubMedGoogle Scholar
  13. 13.
    Berthier CC, Zhang H, Schin M, et al. Enhanced expression of janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes. 2009;58:469–77.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Jordan VC. The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer. 2015;22:R1–31.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Baschant U, Culemann S, Tuckermann J. Molecular determinants of glucocorticoid actions in inflammatory joint diseases. Mol Cell Endocrinol. 2013;380:108–18.CrossRefPubMedGoogle Scholar
  16. 16.
    Safdari Y, Khalili M, Farajnia S, et al. Recent advances in head and neck squamous cell carcinoma—a review. Clin Biochem. 2014;47:1195–202.CrossRefPubMedGoogle Scholar
  17. 17.
    Osako MK, Nakagami H, Morishita R. Modification of decoy oligodeoxynucleotides to achieve the stability and therapeutic efficacy. Curr Top Med Chem. 2012;12:1603–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Patel DJ, Phan AT, Kuryavyi V. Human telomere, oncogenic promoter and 5′-UTR G-quadruplexes: diverse higher order DNA and RNA targets for cancer therapeutics. Nucl Acids Res. 2007;35:7429–55.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Siveen KS, Sikka S, Surana R, et al. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta. 2014;1845:136–54.PubMedGoogle Scholar
  20. 20.
    Park MJ, Kim DI, Lim SK, et al. High glucose-induced O-GlcNAcylated carbohydrate response element-binding protein (ChREBP) mediates mesangial cell lipogenesis and fibrosis: the possible role in the development of diabetic nephropathy. J Biol Chem. 2014;289:13519–30.Google Scholar
  21. 21.
    He Z, Jiang T, Wang Z, et al. Modulation of carbohydrate response element-binding protein gene expression in 3T3-L1 adipocytes and rat adipose tissue. Am J Physiol Endocrinol Metab. 2004;287:E424–30.CrossRefPubMedGoogle Scholar
  22. 22.
    Noordeen NA, Khera TK, Sun G, et al. Carbohydrate-responsive element-binding protein (ChREBP) is a negative regulator of ARNT/HIF-1beta gene expression in pancreatic islet beta-cells. Diabetes. 2010;59:153–60.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Wu L, Chen H, Zhu Y, et al. Flightless I homolog negatively regulates ChREBP activity in cancer cells. Int J Biochem Cell Biol. 2013;45(11):2688–97.CrossRefPubMedGoogle Scholar
  24. 24.
    Kawaguchi T, Takenoshita M, Kabashima T, Uyeda K. Glucose and cAMP regulate the L-type pyruvate kinase gene by phosphorylation/dephosphorylation of the carbohydrate response element binding protein. Proc Natl Acad Sci USA. 2001;98:13710–5.Google Scholar
  25. 25.
    Isoe T, Makino Y, Mizumoto K, et al. High glucose activates HIF-1-mediated signal transduction in glomerular mesangial cells through a carbohydrate response element binding protein. Kidney Int. 2010;78:48–59.CrossRefPubMedGoogle Scholar
  26. 26.
    Tebay LE, Robertson H, Durant ST, et al. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. Free Radic Biol Med. 2015;. doi: 10.1016/j.freeradbiomed.2015.06.021.PubMedGoogle Scholar
  27. 27.
    Zheng H, Whitman SA, Wu W, et al. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes. 2011;60:3055–66.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Cui W, Bai Y, Miao X, et al. Prevention of diabetic nephropathy by sulforaphane: possible role of Nrf2 upregulation and activation. Oxid Med Cell Longev. 2012;2012:821936.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369:2492–503.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Japan Diabetes Society 2015

Authors and Affiliations

  1. 1.Division of Metabolism and Biosystemic Science, Department of MedicineAsahikawa Medical UniversityAsahikawaJapan

Personalised recommendations